Drugs / ALN-VSP02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01158079 | Jul 2010 → Aug 2012 | cancer | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00882180 | Mar 2009 → Jul 2011 | cancer | Alnylam Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2012-06-04 | Alnylam Pharmaceuticals | Results Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. |
| 2011-06-04 | Alnylam Pharmaceuticals | Results Alnylam Presents Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting alnylam.com ↗
In this Phase I study, ALN-VSP was generally well tolerated, demonstrated evidence for anti-tumor activity, and was found to mediate RNAi activity in both hepatic and extra-hepatic tumors. |
| 2011-05-18 | Alnylam Pharmaceuticals | Results Alnylam's ALN-VSP Abstract Published by American Society of Clinical Oncology (ASCO) alnylam.com ↗ |
| 2010-12-16 | Alnylam Pharmaceuticals | Results Alnylam Presents New Data on Delivery of RNAi Therapeutics and Human Translation alnylam.com ↗
Also presented at the Pacifichem meeting were new data from the company’s ALN-VSP02 Phase I clinical study in patients with advanced malignancies with liver involvement. |
| 2010-06-07 | Alnylam Pharmaceuticals | Results Alnylam Presents Preliminary Phase I Data at American Society of Clinical Oncology (ASCO) Meeting for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. |
| 2010-05-20 | Alnylam Pharmaceuticals | Results Alnylam's ALN-VSP Abstract Published by American Society of Clinical Oncology (ASCO) alnylam.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-VSP02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01158079 ↗ |
| Modality | Small interfering RNA (siRNA) | “intravenous ALN-VSP02, an RNAi therapeutic” NCT00882180 ↗ |
| Route | Intravenous | “IV infusion administered every two weeks” NCT00882180 ↗ |